SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Association of Prescription Abandonment with Cost Share for High-Cost Specialty Pharmacy Medications
2 references·4 citing·19 second hop
Association of Prescription Abandonment with Cost Share for High-Cost Specialty Pharmacy Medications (2009)Association of Prescription Abandonment w…Income, Poverty, and Health Insurance Coverage In The United States: 2006 (2007)Income, Poverty, and Health I…Benefit Design And Specialty Drug Use (2006)Benefit Design And Specialty …The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review (2023)The association between cost …Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions (2022)Many Medicare Beneficiaries D…Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence (2020)Patient-reported financial to…Out-of-pocket costs are on the rise for commonly prescribed neurologic medications (2019)Out-of-pocket costs are on th…Patent Buy-Outs: A Mechanism for Encouraging Innovation (1997)A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. (2001)Pharmacy Benefits and the Use of Drugs by the Chronically Ill (2004)Innovation and the welfare effects of public drug insurance (2008)Out-of-Pocket Medication Costs and Use of Medications and Health Care Services Among Children With Asthma (2012)Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States (2017)Problems Paying Out-of-Pocket Medication Costs Among Older Adults With Diabetes (2004)The cost of multiple sclerosis drugs in the US and the pharmaceutical industry (2015)For Working-Age Cancer Survivors, Medical Debt And Bankruptcy Create Financial Hardships (2016)Discrimination and racial disparities in health: evidence and needed research (2008)The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) (2016)Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions (2011)Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia (2013)Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents (2017)Chronic Disease Prevalence in the US: Sociodemographic and Geographic Variations by Zip Code Tabulation Area (2024)Economic Growth and Subjective Well-Being: Reassessing the Easterlin Paradox (2008)Childhood Poverty, Chronic Stress, Self-Regulation, and Coping (2012)The nature of social dominance orientation: Theorizing and measuring preferences for intergroup inequality using the new SDO₇ scale. (2015)
this work references cited by second hop

References

  • 2007Income, Poverty, and Health Insurance Coverage In The United States: 20061,636 cited
  • 2006Benefit Design And Specialty Drug Use122 cited

Cited by

  • 2022Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions82 cited
  • 2019Out-of-pocket costs are on the rise for commonly prescribed neurologic medications54 cited
  • 2023The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review48 cited
  • 2020Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence47 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work